bioMérieux completed the acquisition of certain assets of Day Zero Diagnostics for $25m.

bioMérieux, a diagnostic systems, reagents, software, and services provider, completed the acquisition of certain assets of Day Zero Diagnostics, a company focused on revolutionizing infectious disease diagnostics using whole-genome sequencing and artificial intelligence, for $25m. “The acquisition of Day Zero Diagnostics’ next-generation sequencing assets is a strategic fit with bioMérieux’s long-term vision. Once fully developed, it will complement our existing infectious diseases diagnostic solutions already available on the market. By bringing sequencing technologies into routine fully automated testing, we will provide clinicians with an additional, powerful tool—especially valuable in cases of suspected bloodstream infections or other critical conditions where rapid, actionable results are essential for patient care. This investment reflects bioMérieux’s ongoing commitment to innovation and our mission to advance public health worldwide,” Pierre Boulud, bioMérieux Chief Executive Officer.